SciTech Development Invited to NYC Oncology Investor Conference November 12-13, 2019
SciTech will be presenting its ST-001 nanoFenretinide technology, which is a small-molecule cancer drug employing a nanoparticle suspension for intravenous administration. ST-001 is comprised of fenretinide in a patented combination with carefully selected non-toxic phospholipids. SciTech's product pipeline includes fenretinide formulations for the treatment of several cancer indications. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | (313) 263-4887 | email@example.com
The company has submitted an Investigational New Drug (IND) Application for ST-001 nanoFenretinide and the FDA has granted it Orphan Drug Status for the treatment of two types of non-Hodgkin's lymphoma (NHL): peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Information regarding SciTech's nano formulation technology and oncology drug product ST-001 nanoFenretinide is available from SciTech Development, LLC by calling +1-313-938-5517 or online at https://www.scitechdevelopment.com/
About SciTech Development
SciTech Development, LLC is a clinical stage drug development company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland.
SciTech Development LLC